Antigenic modulation by trogocytosis during anti-CD20 mAb treatment with rituximab (RTX) leads to loss of CD20 and therefore can compromise therapy. During trogocytosis, effector cells, such as macrophages, remove CD20 from the surface of antibody-coated cells in an
Fc receptor-dependent manner. Importantly, Fc
纬 receptors (Fc
纬Rs) are also crucial in the anti-tumor effects of RTX by inducing antibody dependent cell-mediated cytotoxicity (ADCC). Here we studied the role of Fc
纬R during RTX-induced trogocytosis of CD20 in an intraperitoneal tumor model with EL4-CD20 cells. We found marked RTX-induced trogocytosis of CD20 in Fc
纬RI- or Fc
纬RIII-deficient mice, similar to wild type mice, demonstrating a redundancy for activating Fc
纬R in trogocytosis. Interestingly, in FcR
纬-chain-deficient mice, trogocytosis was still apparent, indicating that the inhibitory receptor Fc
纬RIIB alone can also mediate trogocytosis. These data were confirmed by
in vitro analysis with blocking antibodies. Decreasing the amount of RTX
in vivo resulted in less trogocytosis of CD20, supporting clinical studies with lower RTX dose. Importantly, we show that cells which undergo
in vivo trogocytosis can still be killed
ex vivo by ADCC but not by complement-mediated cytotoxicity (CDC), underscoring the clinical relevance of trogocytosis.
Taken together, our study provides more insights into the mechanism and consequences of RTX-induced trogocytosis of CD20.